Convirox 150 mg Cápsulas Ecuador - spagnolo - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

convirox 150 mg cápsulas

oxialfarm cia ltda [ec] ecuador - atazanavir sulfato 0.170 g (equivalente a 150 mg de atazanavir base) - capsula - cada cápsula contiene: atazanavir sulfato 0.170 g (equivalente a 150 mg de atazanavir base)

ANZAVIR 300 mg CAPSULAS Venezuela - spagnolo - Instituto Nacional de Higiene

anzavir 300 mg capsulas

pediatrics pharma, c.a. - atazanavir - capsulas - 300 mg

REYATAZ 150 mg CAPSULAS Venezuela - spagnolo - Instituto Nacional de Higiene

reyataz 150 mg capsulas

bristol-myers de venezuela, s.c.a. - atazanavir sulfato - c - 150 mg

REYATAZ 200 mg CAPSULAS Venezuela - spagnolo - Instituto Nacional de Higiene

reyataz 200 mg capsulas

bristol-myers de venezuela, s.c.a. - atazanavir sulfato - c - 200 mg

REYDUO COMPRIMIDOS RECUBIERTOS Cile - spagnolo - ISPC (Instituto de Salud Pública de Chile)

reyduo comprimidos recubiertos

bristol - myers squibb de chile - atazanavir; cobicistat - sin formulas

REYATAZ 100 mg CAPSULAS Venezuela - spagnolo - Instituto Nacional de Higiene

reyataz 100 mg capsulas

bristol-myers de venezuela, s.c.a. - atazanavir sulfato - capsula - 100 mg

Triumeq Unione Europea - spagnolo - EMA (European Medicines Agency)

triumeq

viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - infecciones por vih - antivirales para uso sistémico - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults,  adolescents and children  weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.

Tybost Unione Europea - spagnolo - EMA (European Medicines Agency)

tybost

gilead sciences ireland uc - cobicistat - infecciones por vih - antivirales para uso sistémico - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.